

wherein Xaa at the beginning of each said polypeptide and Xaa at the end of each said polypeptide are independently from 0 to about 5 naturally occurring amino acids, wherein n is 1 to about 1000, wherein the polypeptide is capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease.

REMARKS


Applicants thank the Examiner for the telephone conference on December 17, 1998 with applicants' attorney of record, providing the appropriate way to identify the amino acids at the beginning and at the end of the polypeptide, as provided in SEQ. ID. NOS. 7-10. Applicants respectfully request the entry of the Amendment, the Substitute Paper Copy Sheet of the "Sequence Listing," the Substitute Computer Readable Form disk, and the Statement pursuant to 37 C.F.R. §1.821(f), enclosed herein into the specification of the application. Applicants state that no new matter has been added.

Applicants have amended claim 1 to reflect the submission of SEQ. ID. NOS. 7- 10. The amendment to claim 1 does not add any new matter.

Respectfully Submitted,

Loeb & Loeb LLP

Date: December 21, 1998



ELLEN S. KIM

Reg. No. 42,729

Attorney for Applicants

Law Offices of
Loeb & Loeb LLP
10100 Santa Monica Blvd. Suite 2200
Los Angeles, California 90067
Telephone: 310-282-2000
Facsimile: 310-282-2192